title: [Are beta-blockers generally contraindicated in patients with peripheral arterial occlusive disease?].
abstract: Ninety patients with chronic ischemic heart disease and stage IIb peripheral arterial occlusive disease were investigated to determine the effect of celiprolol, atenolol and isosorbide dinitrate on peripheral arterial blood flow. Walking distance and the resistance index in the femoral artery were measured before and after 3 months medication and compared with the findings in controls (30 patients with chronic ischemic heart disease and stage IIb peripheral arterial occlusive disease) who received placebo. Patients with peripheral arterial occlusive disease who were treated with atenolol 50 mg/day demonstrated significant decreases in both pain-free and maximal walking distance. In contrast, the walking distances in those given celiprolol 200 mg/day and those who received isosorbide dinitrate 80 mg/day did not differ from the distances in control subjects. The Doppler flow through the femoral artery, as measured by color duplex sonography, showed a significant decrease in resistance index, both in patients given celiprolol and in those given isosorbide dinitrate. In patients treated with atenolol the resistance index rose significantly. The results of this study confirm that the beta-adrenoceptor blocker celiprolol exerts a supplementary vasodilatory action resembling that of nitrates and hence can be used in patients with chronic ischemic heart disease and impaired peripheral arterial perfusion.
authors.affiliation: II. Medizinische Klinik, Städtisches Klinikum Dresden-Friedrichstadt.
authors.forename: J
authors.initials: J
authors.lastname: Schweizer
authors.forename: R
authors.initials: R
authors.lastname: Kaulen
authors.forename: E
authors.initials: E
authors.lastname: Altmann
authors.forename: A
authors.initials: A
authors.lastname: Nierade
authors.forename: T
authors.initials: T
authors.lastname: Nanning
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D001262:Atenolol / Q000627:therapeutic use; D001783:Blood Flow Velocity / Q000187:drug effects; D017272:Celiprolol / Q000627:therapeutic use; D000075202:Contraindications; D003327:Coronary Disease / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005080:Exercise Test / Q000187:drug effects; D005260:Female; D006801:Humans; D007511:Ischemia / Q000188:drug therapy; D007548:Isosorbide Dinitrate / Q000627:therapeutic use; D007866:Leg / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D014665:Vasodilator Agents; D001262:Atenolol; D017272:Celiprolol; D007548:Isosorbide Dinitrate
vernacular_title: Sind Betablocker bei Patienten mit peripherer arterieller Verschlusskrankheit generell kontraindiziert?